Giant cell myocarditis after first dose of BNT162b2 - a case report.

Autor: Hirsch VG; Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany., Schallhorn S; Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany., Zwadlo C; Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany., Diekmann J; Department of Nuclear Medicine, Hannover Medical School, Hannover, Germany., Länger F; Institute of Pathology, Hannover Medical School, Hannover, Germany., Jonigk DD; Institute of Pathology, Hannover Medical School, Hannover, Germany., Kempf T; Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany., Schultheiss HP; Institute of Cardiac Diagnostics and Therapy, IKDT GmbH, Berlin, Germany., Bauersachs J; Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany.
Jazyk: angličtina
Zdroj: European journal of heart failure [Eur J Heart Fail] 2022 Jul; Vol. 24 (7), pp. 1319-1322. Date of Electronic Publication: 2022 Jul 11.
DOI: 10.1002/ejhf.2590
Abstrakt: Herein we report the case of a young man, admitted to the Department of Cardiology and Angiology at Hannover Medical School with shortness of breath and elevated troponin. Few weeks earlier the patient received the first dose of BioNTech's mRNA vaccine (Comirnaty, BNT162b2). After diagnostic work-up revealed giant cell myocarditis, the patient received immunosuppressive therapy. In the present context of myocarditis after mRNA vaccination we discuss this rare aetiology and the patient's treatment strategy in the light of current recommendations.
(© 2022 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje